What does this research mean for the field?

MYCN-amplified neuroblastoma drives an 'immune desert' tumor microenvironment characterized by severe T and B lymphocyte depletion, where immune evasion is mediated by REL/EOMES upregulation in T cells and a unique immunosuppressive B-cell subset. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To systematically determine how MYCN amplification induces an immunosuppressive tumor microenvironment and mediates immune evasion in high-risk neuroblastoma.

September 3, 2026CNS Neuroscience & TherapeuticsOpen Access

Integrated Genomic and Proteomic Analysis Reveals T‐B Lymphocyte Signatures in the MYCN Driven “Immune Desert” of Specific Neuroblastoma Subtypes

View Full Paper

Ask AI

Bookmark

Authors

JHJia‐jian Hu WKWenjuan Kang HJHU Jia-tong

Discussion

Member takes

Overview

Multi-omics analysis reveals immunosuppressive lymphocyte networks in MYCN-amplified neuroblastoma, highlighting REL inhibition and specific cell axes as candidate therapeutic targets.

Key Points

To systematically determine how MYCN amplification induces an immunosuppressive tumor microenvironment and mediates immune evasion in high-risk neuroblastoma.
Conducted an integrated multi-omics analysis analyzing bulk RNA-seq (n = 721), single-cell RNA-seq (n = 9), proteomic profiling (n = 49), and spatial transcriptomics.
Performed unsupervised clustering, cellular communication inference, transcriptional network reconstruction, and spatial proximity evaluation.
Identified a MYCN-amplified poor-prognosis subtype (Class C) exhibiting an immune desert phenotype marked by severe depletion of infiltrating T and B lymphocytes.
Uncovered T-cell transcriptional dysregulation mediated by EOMES and REL, where REL inhibition restored cytotoxic T-cell activity in vitro and elevated REL protein was validated by proteomics.
Identified an immunosuppressive B-cell subset (B7) governed by a MYC-centric network that spatially co-localized with regulatory and exhausted T cells.

Cite This Study

Hu et al. (2026) studied this question.

synapsesocial.com/papers/6a99351f636c6408cfa7d15a https://doi.org/10.1002/cns.71054

View Full Paper

Ask AI

Bookmark

September 3, 2026CNS Neuroscience & TherapeuticsOpen Access

Integrated Genomic and Proteomic Analysis Reveals T‐B Lymphocyte Signatures in the MYCN Driven “Immune Desert” of Specific Neuroblastoma Subtypes

View Full Paper

Ask AI

Bookmark

Authors

JHJia‐jian Hu WKWenjuan Kang HJHU Jia-tong

Discussion

Member takes

Overview

Multi-omics analysis reveals immunosuppressive lymphocyte networks in MYCN-amplified neuroblastoma, highlighting REL inhibition and specific cell axes as candidate therapeutic targets.

Key Points

To systematically determine how MYCN amplification induces an immunosuppressive tumor microenvironment and mediates immune evasion in high-risk neuroblastoma.
Conducted an integrated multi-omics analysis analyzing bulk RNA-seq (n = 721), single-cell RNA-seq (n = 9), proteomic profiling (n = 49), and spatial transcriptomics.
Performed unsupervised clustering, cellular communication inference, transcriptional network reconstruction, and spatial proximity evaluation.
Identified a MYCN-amplified poor-prognosis subtype (Class C) exhibiting an immune desert phenotype marked by severe depletion of infiltrating T and B lymphocytes.
Uncovered T-cell transcriptional dysregulation mediated by EOMES and REL, where REL inhibition restored cytotoxic T-cell activity in vitro and elevated REL protein was validated by proteomics.
Identified an immunosuppressive B-cell subset (B7) governed by a MYC-centric network that spatially co-localized with regulatory and exhausted T cells.

Cite This Study

Hu et al. (2026) studied this question.

synapsesocial.com/papers/6a99351f636c6408cfa7d15a https://doi.org/10.1002/cns.71054

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark